Hanbyeol Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hanbyeol Kim has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Chul-Hwan Lee
Seoul National University
5 shared publications - Kyumin Park
Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Korea
2 shared publications - Seounghyun Eum
Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Korea
2 shared publications - Soo Hyun Lee
Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Korea
2 shared publications - Yingying Li
Department of Pharmacology, Seoul National University College of Medicine , Seoul, 03080
2 shared publications - Anna Cho
Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Korea
1 shared publication
Latest Publications
- 23 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (124) , eadz0989
ILC2-derived IL-9 promotes eosinophil-mediated antitumor activity
Innate lymphoid cells (ILCs) regulate tissue immunity, yet their roles in tumor control remain incompletely understood. Here, we combined analyses of human sequencing datasets with genetic ablation mouse models and adoptive transfer experiments to identify that glucocorticoid-induced tumor necrosis factor receptor (GITR) engagement on tumor-infiltrating group 2 ILCs (ILC2s) induced activating transcription factor 3 (ATF3) and robust interleukin-9 (IL-9) production, exceeding the modest coinduction of IL-5 and IL-13. ILC2-derived IL-9 promoted intratumoral eosinophil accumulation by enhancing survival, tissue retention, and cytotoxicity through tumor-induced IL-9 receptor expression. Eosinophil ablation abolished GITR-mediated tumor control, whereas adoptive eosinophil transfer restored it. This IL-9–eosinophil pathway suppressed tumor growth in the absence of adaptive lymphocytes. In human datasets, IL-9 and eosinophil signatures were associated with favorable prognosis in melanoma and lung adenocarcinoma. These findings define an innate pathway linking ILC2s to eosinophil-mediated tumor immunity and support GITR agonism as a therapeutic strategy.
- 23 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (124) , eadz0989
ILC2-derived IL-9 promotes eosinophil-mediated antitumor activity
Innate lymphoid cells (ILCs) regulate tissue immunity, yet their roles in tumor control remain incompletely understood. Here, we combined analyses of human sequencing datasets with genetic ablation mouse models and adoptive transfer experiments to identify that glucocorticoid-induced tumor necrosis factor receptor (GITR) engagement on tumor-infiltrating group 2 ILCs (ILC2s) induced activating transcription factor 3 (ATF3) and robust interleukin-9 (IL-9) production, exceeding the modest coinduction of IL-5 and IL-13. ILC2-derived IL-9 promoted intratumoral eosinophil accumulation by enhancing survival, tissue retention, and cytotoxicity through tumor-induced IL-9 receptor expression. Eosinophil ablation abolished GITR-mediated tumor control, whereas adoptive eosinophil transfer restored it. This IL-9–eosinophil pathway suppressed tumor growth in the absence of adaptive lymphocytes. In human datasets, IL-9 and eosinophil signatures were associated with favorable prognosis in melanoma and lung adenocarcinoma. These findings define an innate pathway linking ILC2s to eosinophil-mediated tumor immunity and support GITR agonism as a therapeutic strategy.
- Open Access
EZH1 Q571R-mediated chromatin compaction and its oncogenic potential in thyroid cancer
Summary: Dysregulation of Polycomb Repressive Complex 2 (PRC2) is established to contribute to cancer. Of its catalytic subunits, EZH1 and EZH2, EZH2 mutations in cancer have been extensively identified and studied, but the role of EZH1 in cancer remains largely unexplored. The recurrent presence of the EZH1 Q571R mutation in follicular thyroid cancer suggests its involvement in tumor progression. Using EZH1 ChIP-seq, ATAC-seq, and H3K27me3 CUT&Tag, we demonstrated that EZH1 Q571R enhances chromatin binding and compaction and stimulates PRC2-EZH1 catalytic activity, leading to increased H3K27me3 levels and repression of tumor suppressor genes. Purified PRC2-EZH1 Q571R demonstrated a significant increase in histone methyltransferase activity compared to PRC2-EZH1 WT via enhanced nucleosome binding and DNA compaction. Notably, this effect is particularly observed with EZH1 Q571R but only to a lesser extent with the corresponding EZH2 Q570R mutation, highlighting it as an EZH1-specific mechanism. We additionally demonstrated PRC2-EZH1 Q571R to efficiently methylate H3K27 in pre-existing H3K36me2/3 nucleosomes, disrupting chromatin homeostasis. Our findings provide key insights into the molecular pathogenesis of EZH1 Q571R -driven follicular thyroid cancer.
Open AccessEZH1 Q571R-mediated chromatin compaction and its oncogenic potential in thyroid cancer
Summary: Dysregulation of Polycomb Repressive Complex 2 (PRC2) is established to contribute to cancer. Of its catalytic subunits, EZH1 and EZH2, EZH2 mutations in cancer have been extensively identified and studied, but the role of EZH1 in cancer remains largely unexplored. The recurrent presence of the EZH1 Q571R mutation in follicular thyroid cancer suggests its involvement in tumor progression. Using EZH1 ChIP-seq, ATAC-seq, and H3K27me3 CUT&Tag, we demonstrated that EZH1 Q571R enhances chromatin binding and compaction and stimulates PRC2-EZH1 catalytic activity, leading to increased H3K27me3 levels and repression of tumor suppressor genes. Purified PRC2-EZH1 Q571R demonstrated a significant increase in histone methyltransferase activity compared to PRC2-EZH1 WT via enhanced nucleosome binding and DNA compaction. Notably, this effect is particularly observed with EZH1 Q571R but only to a lesser extent with the corresponding EZH2 Q570R mutation, highlighting it as an EZH1-specific mechanism. We additionally demonstrated PRC2-EZH1 Q571R to efficiently methylate H3K27 in pre-existing H3K36me2/3 nucleosomes, disrupting chromatin homeostasis. Our findings provide key insights into the molecular pathogenesis of EZH1 Q571R -driven follicular thyroid cancer.
- Open Access
- 14 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (11) , eadr4443
Inhibiting EZH2 complements steroid effects in Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a devastating X-linked disorder caused by dystrophin gene mutations. Despite recent advances in understanding the disease etiology and applying emerging treatment methodologies, glucocorticoid derivatives remain the only general therapeutic option that can slow disease development. However, the precise molecular mechanism of glucocorticoid action remains unclear, and there is still need for additional remedies to complement the treatment. Here, using single-nucleus RNA sequencing and spatial transcriptome analyses of human and mouse muscles, we investigated pathogenic features in patients with DMD and palliative effects of glucocorticoids. Our approach further illuminated the importance of proliferating satellite cells and revealed increased activity of a signal transduction pathway involving EZH2 in the patient cells. Subsequent administration of EZH2 inhibitors to Dmd mutant mice resulted in improved muscle phenotype through maintaining the immune-suppressing effect but overriding the muscle weakness and fibrogenic effects exerted by glucocorticoids. Our analysis reveals pathogenic mechanisms that can be readily targeted by extant therapeutic options for DMD.
- 14 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (11) , eadr4443
Open AccessInhibiting EZH2 complements steroid effects in Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a devastating X-linked disorder caused by dystrophin gene mutations. Despite recent advances in understanding the disease etiology and applying emerging treatment methodologies, glucocorticoid derivatives remain the only general therapeutic option that can slow disease development. However, the precise molecular mechanism of glucocorticoid action remains unclear, and there is still need for additional remedies to complement the treatment. Here, using single-nucleus RNA sequencing and spatial transcriptome analyses of human and mouse muscles, we investigated pathogenic features in patients with DMD and palliative effects of glucocorticoids. Our approach further illuminated the importance of proliferating satellite cells and revealed increased activity of a signal transduction pathway involving EZH2 in the patient cells. Subsequent administration of EZH2 inhibitors to Dmd mutant mice resulted in improved muscle phenotype through maintaining the immune-suppressing effect but overriding the muscle weakness and fibrogenic effects exerted by glucocorticoids. Our analysis reveals pathogenic mechanisms that can be readily targeted by extant therapeutic options for DMD.
- Open Access
- 31 December 2022
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 55 (12) , 595-601
The role of EZH1 and EZH2 in development and cancer
Soo Hyun Lee, Yingying Li, Hanbyeol Kim, Seounghyun Eum, Kyumin Park & Chul-Hwan Lee. BMB Reports 2022;55:595-601. https://doi.org/10.5483/BMBRep.2022.55.12.174
- 31 December 2022
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 55 (12) , 595-601
Open AccessThe role of EZH1 and EZH2 in development and cancer
Soo Hyun Lee, Yingying Li, Hanbyeol Kim, Seounghyun Eum, Kyumin Park & Chul-Hwan Lee. BMB Reports 2022;55:595-601. https://doi.org/10.5483/BMBRep.2022.55.12.174
- 29 November 2022
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
The role of EZH1 and EZH2 in development and cancer
- 29 November 2022
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
The role of EZH1 and EZH2 in development and cancer